Comparative Pharmacology
Head-to-head clinical analysis: PEDIAPRED versus RAYOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEDIAPRED versus RAYOS.
PEDIAPRED vs RAYOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prednisolone is a glucocorticoid receptor agonist that binds to the intracellular glucocorticoid receptor, leading to modulation of gene expression. It suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production (e.g., IL-1, IL-6, TNF-alpha). It also suppresses immune responses by reducing lymphocyte proliferation and activity.
Synthetic glucocorticoid with anti-inflammatory, immunosuppressive, and metabolic effects; binds to glucocorticoid receptor, modulating gene expression and inhibiting phospholipase A2, cytokine production, and immune cell activity.
Oral: 5-60 mg/day as a single dose or divided doses; adjust based on condition and response.
Initial adult dose 5-60 mg orally once daily, adjusted based on disease severity and response. Typically administered as a single dose in the morning with food.
None Documented
None Documented
2.5–3.5 hours (terminal) in children; clinical context: requires multiple daily doses for sustained effect.
2-3 hours (terminal); prolonged in hepatic impairment; circadian-timed formulation intended for once-daily morning dosing.
Renal: ~80% as metabolites (mainly glucuronides and sulfates) and <5% unchanged; fecal: ~15%.
Renal: ~80% as inactive metabolites; fecal: ~5%; biliary: small amount.
Category C
Category C
Corticosteroid
Corticosteroid